Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › IA › Sioux City › NPI 1962594622
Hospital

Northwest Iowa Hospital Corporation

Northwest Iowa Hospital Corporation was paid $22.86M by Medicaid between Jan 2018 and Dec 2024, across 145 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.

33Billing provider infoNORTHWEST IOWA HOSPITAL CORPORATION
SIOUX CITY, IA 51104
33aNPI1962594622assigned 09/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.86M
24GClaims411,957
24DCodes billed145
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Iowa

Rank by total paid#6 of 29
Median peer was paid$6.37M
This provider vs. median3.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201848,901$2.95M
201957,943$3.25M
202041,460$2.39M
202163,941$3.65M
202278,755$4.42M
202380,867$4.31M
2024incomplete40,090$1.90M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 30% 26,963 25,365 $6.90M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 25% 32,841 31,172 $5.63M
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 6.6% 60,877 57,538 $1.51M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 6.3% 3,699 3,428 $1.43M
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 6.2% 11,940 10,795 $1.42M
96361 Intravenous infusion, hydration; each additional hour 4.9% 9,875 7,750 $1.11M
G0463 Hospital outpatient clinic visit for assessment and management of a patient 3.0% 7,834 6,845 $679K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 2.5% 5,267 4,977 $573K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 2.0% 6,196 5,797 $453K
G0330 Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room 1.2% 154 153 $277K
59025 Fetal non-stress test 1.2% 1,962 1,161 $270K
71046 Radiologic examination, chest; 2 views 1.2% 4,801 4,516 $264K
133 more codes
96375 Therapeutic injection; each additional sequential IV push 1.0% 7,721 $230K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 487 $155K
77067 Screening mammography, bilateral, including computer-aided detection <1% 1,485 $132K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 3,745 $129K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 3,761 $108K
87081 <1% 15,551 $97K
36415 Collection of venous blood by venipuncture <1% 35,164 $73K
87806 <1% 2,755 $72K
77063 Screening digital breast tomosynthesis, bilateral <1% 1,484 $72K
84443 Thyroid stimulating hormone (TSH) <1% 5,489 $71K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 6,107 $69K
D2930 Prefabricated stainless steel crown - primary tooth <1% 147 $61K
47562 <1% 13 $60K
80053 Comprehensive metabolic panel <1% 25,892 $58K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 568 $58K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 2,791 $55K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 1,776 $52K
71045 Radiologic examination, chest; single view <1% 849 $49K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 34,196 $49K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 865 $46K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 1,243 $43K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 335 $42K
86803 <1% 3,455 $41K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 132 $39K
G0378 Hospital observation service, per hour <1% 1,095 $36K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 43 $33K
87340 <1% 3,429 $30K
99213 Doctor's office visit, returning patient (routine) <1% 340 $28K
80048 Basic metabolic panel (calcium, ionized) <1% 8,226 $28K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 1,532 $27K
87631 <1% 470 $19K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 307 $19K
86780 <1% 1,662 $18K
76642 <1% 283 $18K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 168 $17K
0353U <1% 1,182 $17K
80076 <1% 1,548 $10K
80061 Lipid panel <1% 913 $10K
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 39 $10K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 3,984 $9K
87634 <1% 1,120 $9K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 458 $9K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 95 $9K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 365 $9K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder <1% 111 $8K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,849 $8K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 6,981 $8K
83655 <1% 722 $8K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 4,926 $7K
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 69 $6K
85027 <1% 2,599 $6K
G0279 Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) <1% 129 $5K
86592 <1% 973 $3K
86480 <1% 62 $3K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 30 $3K
70450 Computed tomography, head or brain; without contrast material <1% 29 $3K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 1,149 $3K
J2785 Injection, regadenoson, 0.1 mg <1% 55 $3K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 20 $3K
90853 Group psychotherapy (other than of a multiple-family group) <1% 134 $2K
93296 <1% 118 $2K
99214 Doctor's office visit, returning patient (more involved) <1% 13 $2K
G0432 Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening <1% 174 $2K
81015 <1% 4,451 $2K
J2704 Injection, propofol, 10 mg <1% 647 $2K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 68 $2K
87899 <1% 174 $2K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 33 $2K
94010 <1% 2,449 $2K
80055 <1% 44 $2K
77066 Tomosynthesis, mammo <1% 13 $1K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 1,612 $1K
76830 Ultrasound, transvaginal <1% 16 $1K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 912 $1K
86140 <1% 5,212 $1K
85018 <1% 466 $1K
83036 Hemoglobin; glycosylated (A1C) <1% 178 $1K
97535 Self-care/home management training, each 15 minutes <1% 21 $961.32
85007 <1% 650 $904.54
36416 <1% 120 $694.15
J3010 Injection, fentanyl citrate, 0.1 mg <1% 630 $624.40
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 97 $594.45
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 402 $549.86
87210 <1% 110 $526.88
87070 <1% 39 $521.61
J1170 Injection, hydromorphone, up to 4 mg <1% 307 $495.02
87077 <1% 115 $489.59
83690 <1% 4,343 $452.95
93017 <1% 59 $380.72
88304 <1% 87 $323.69
J3490 Unclassified drugs <1% 49 $291.01
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 300 $248.45
A9270 Non-covered item or service <1% 983 $237.92
84703 <1% 2,913 $237.51
84439 <1% 50 $170.26
87186 <1% 43 $148.67
86900 <1% 13 $146.85
J2270 Injection, morphine sulfate, up to 10 mg <1% 219 $141.66
83735 <1% 97 $140.14
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 92 $125.61
76942 <1% 58 $113.61
81001 <1% 2,113 $105.09
J0694 Injection, cefoxitin sodium, 1 gm <1% 32 $71.10
81002 <1% 15 $52.72
83880 <1% 25 $39.26
J7120 Ringers lactate infusion, up to 1000 cc <1% 386 $39.00
81003 <1% 388 $37.61
84484 <1% 1,126 $25.07
86901 <1% 13 $23.90
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 212 $22.51
94729 <1% 77 $6.93
J2710 Injection, neostigmine methylsulfate, up to 0.5 mg <1% 17 $3.60
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge <1% 456 $2.33
J2175 Injection, meperidine hydrochloride, per 100 mg <1% 12 $0.75
84145 0% 13 $0.00
A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose 0% 56 $0.00
J7030 Infusion, normal saline solution , 1000 cc 0% 38 $0.00
80179 0% 19 $0.00
J1200 Injection, diphenhydramine hcl, up to 50 mg 0% 16 $0.00
81025 0% 13 $0.00
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 0% 16 $0.00
80143 0% 22 $0.00
83605 0% 313 $0.00
96376 0% 467 $0.00
87040 0% 83 $0.00
99406 0% 32 $0.00
82962 0% 14 $0.00
83874 0% 13 $0.00
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen 0% 13 $0.00
82553 0% 13 $0.00
82550 0% 13 $0.00
0352U 0% 17 $0.00
80320 0% 20 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialARNOLD, JANE (MARKET PRESIDENT)